Institute of Medicinal Biotechnology;
Chinese Academy of Medical Sciences;
Peking Union Medical College;
Beijing 100050;
China;
Drug combination; Esophageal adenocarcinoma; Esophageal squamous cell carcinoma; Immune therapy; Molecular targeted therapy;